Navigation Links
Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2007 Financial and Operating Results on March 5, 2008
Date:2/28/2008

QUEBEC CITY, Feb. 28 /PRNewswire-FirstCall/ - Aeterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ), a global biopharmaceutical company focused on endocrine therapy and oncology, will announce its fourth quarter and full-year 2007 financial and operating results before market open on Wednesday, March 5, 2008. The Company will host a conference call and webcast to discuss these results later that same day at 10:00 a.m., Eastern Time.

Participants may access the live webcast via the Company's website at http://www.aezsinc.com in the "Investors" section, or by telephone using the following numbers: 416-644-3425, 514-807-8791 or 800-595-8550. A replay of the webcast will also be available on the Company's website for a period of 30 days.

About Aeterna Zentaris Inc.

Aeterna Zentaris Inc. is global biopharmaceutical company focused on endocrine therapy and oncology with proven expertise in drug discovery, development and commercialization. News releases and additional information are available at http://www.aezsinc.com.


'/>"/>
SOURCE AETERNA ZENTARIS INC.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. AEterna Zentaris to Present at the Upcoming Roth Capital Partners 20th Annual OC Growth Stock Conference in Dana Point, California
2. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
3. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
4. AEterna Zentaris Announces Outcome of Managements Strategic Review
5. AEterna Zentaris to Present at Upcoming UBS Global Life Sciences Conference in New York
6. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
7. Kosan Announces Senior Management Changes and Clinical Portfolio Priorities
8. Kosan Announces Fourth Quarter and Full Year 2007 Financial Results and 2008 Outlook
9. Wyeth Announces Executive Change in Finance Organization
10. BioCryst Pharmaceuticals to Announce Fourth Quarter and Fiscal Year 2007 Financial Results on March 4, 2008
11. Insmed Announces Listing Transfer from Nasdaq Global Market to Nasdaq Capital Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)...  Pomerantz LLP is investigating claims on behalf of ... (NASDAQ: IPXL).  Such investors are advised to contact ... 888-476-6529, ext. 237. The investigation concerns whether ... violated Sections 10(b) and 20(a) of the Securities Exchange ... 2014, Impax Laboratories, Inc. (the "Company") issued a press ...
(Date:7/29/2014)... 29, 2014 According to the ... Imaging), Analytics (Image Analysis Software), Delivery Modes (Web Based/Cloud ... & Trends to 2018", published by MarketsandMarkets, analyzes and ... such as North America , ... and the Rest of the World (RoW). ...
(Date:7/29/2014)... , July 29, 2014 /PRNewswire-iReach/ -- Nanosyn, Inc. ... FORMA Therapeutics, Inc., to provide access to Nanosyn,s ... lead discovery platform for novel small molecule therapeutics. ... the opportunity to work with FORMA Therapeutics to ... and protein homeostasis. FORMA Therapeutics, decision to work ...
(Date:7/29/2014)... July 29, 2014  Cannabis Science, Inc. (OTC: ... drug development and related consulting, applauds the Editorial ... a strong position in opposition to current federal ... 2014 publication.  The New York Times also announces ... week exploring the issue called "High Time:  An ...
Breaking Biology Technology:SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Impax Laboratories, Inc. - IPXL 2Digital Pathology Market worth $437 Million by 2018 2Digital Pathology Market worth $437 Million by 2018 3Nanosyn Announces Expanded Partnership With FORMA Therapeutics 2Cannabis Science, Inc. (CBIS) Applauds New York Times Editorial Board Stance on 'Repealing Prohibition, Again'; NYT Editorial Is Bell Weather of Change 2Cannabis Science, Inc. (CBIS) Applauds New York Times Editorial Board Stance on 'Repealing Prohibition, Again'; NYT Editorial Is Bell Weather of Change 3
... First Capability To Rapidly Identify Five Candida ... Positive Blood Cultures In One Test, WOBURN, ... FDA 510(k) clearance of the Yeast Traffic Light ... positive blood cultures. The,Yeast Traffic Light(TM) is the ...
... 23 Affitech AS, the Norwegian human,antibody ... accomplished the,second milestone in its research and ... recombinant antibodies against an unnamed oncology,target. Affitech ... Antibody,Screening) system that included its proprietary antibody ...
... 22, 2008 -- Chemists at Rice University have discovered ... tiny, wand-like nanoparticles that are being studied in dozens ... disease and improving electronic viewscreens. , "The content of ... is only about 20 percent," said lead researcher Eugene ...
Cached Biology Technology:AdvanDx Receives FDA 510(k) Clearance for Yeast Traffic Light PNA FISH(TM) 2AdvanDx Receives FDA 510(k) Clearance for Yeast Traffic Light PNA FISH(TM) 3Affitech Announces Second Milestone in Roche Antibody Discovery Collaboration 2Purifying nanorods: Big success with tiny cleanup 2
(Date:7/28/2014)... of people in the United States have a circulatory ... can be painful and may even require surgery in ... muscle wasting and, in turn, limb amputation. , At ... (UTHealth) Medical School, scientists tested a non-surgical preventative treatment ... was associated with increased blood circulation. Their proof-of-concept ...
(Date:7/28/2014)... Solanum pennellii , a wild relative of the ... of researchers including the labs headed by Professors Neelima ... of Plant Biology. The new genome information may help ... published July 27 in the journal Nature Genetics ... Aachen University in Germany. The UC Davis labs carried ...
(Date:7/28/2014)... hunter, but the target of his work consists of ... special methods and instruments. Benjamin Hause, an assistant research ... Kansas State University, recently published an article about one ... important find in the United States. , "We had ... it was," Hause said. "We used next-generation sequencing to ...
Breaking Biology News(10 mins):Scientists discover genetic switch that can prevent peripheral vascular disease in mice 2Researcher using next-generation sequencing to rapidly identify pathogens 2Researcher using next-generation sequencing to rapidly identify pathogens 3
... buzzing around your plate. Its color and motion could both influence ... might decide it was a bee and move away. Conversely, you ... insect away. You perceive both color and motion, and decide based ... heartbeat. The mystery is how. In an article published November ...
... A human clinical study of older adults has demonstrated ... dietary supplement created by Natura Therapeutics, Inc., showed ... individuals taking a placebo. Cognition includes processes such as ... The company,s study, Nutraceutical Intervention Improves Older Adults, Cognitive ...
... early infancy may be a key to early identification of ... of Mental Health (NIMH), part of the National Institutes of ... the study reveals the earliest sign of developing autism ever ... first two to six months of life. "Autism ...
Cached Biology News:Stanford researchers surprised to find how neural circuits identify information needed for decisions 2Stanford researchers surprised to find how neural circuits identify information needed for decisions 3Stanford researchers surprised to find how neural circuits identify information needed for decisions 4Stanford researchers surprised to find how neural circuits identify information needed for decisions 5Natura Therapeutics product shown to improve decision making skills in older adults 2Earliest marker for autism found in young infants 2Earliest marker for autism found in young infants 3